VivoSim Labs, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIVS research report →
Companyvivosim.ai
VivoSim Labs, Inc. , a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
- CEO
- Keith E. Murphy
- IPO
- 2012
- Employees
- 14
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $3.39M
- P/E
- -1.55
- P/S
- 23.88
- P/B
- 0.43
- EV/EBITDA
- 0.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -8066.20%
- Net Margin
- -864.08%
- ROE
- -15.56%
- ROIC
- -228.26%
Growth & Income
- Revenue
- $144.00K · 32.11%
- Net Income
- $-2,488,000 · 83.04%
- EPS
- $-1.70 · 91.17%
- Op Income
- $-12,616,000
- FCF YoY
- 35.53%
Performance & Tape
- 52W High
- $5.30
- 52W Low
- $1.25
- 50D MA
- $1.54
- 200D MA
- $2.15
- Beta
- 1.41
- Avg Volume
- 75.87K
Get TickerSpark's AI analysis on VIVS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 27, 26 | Cohen Douglas Jay | other | 15,000 |
| Jan 27, 26 | Murphy Keith | other | 15,000 |
| Jan 27, 26 | Milhous Alison Tjosvold | other | 15,000 |
| Jan 27, 26 | Gobel David | other | 15,000 |
| Jan 27, 26 | STERN ADAM K | other | 15,000 |
| Nov 25, 25 | Sethi Amar Akhtar | other | 53,500 |
| Nov 24, 25 | Sethi Amar Akhtar | other | 0 |
| Nov 17, 25 | Gobel David | sell | 3,266 |
| Aug 11, 25 | Lialin Tony Serge | other | 40,000 |
| Aug 11, 25 | Lialin Tony Serge | other | 0 |
Our VIVS Coverage
We haven't published any research on VIVS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIVS Report →